Genmab A/S at Goldman Sachs Healthcare Conference Transcript
Okay. Good morning, everyone. My name is Rajan Sharma. I'm one of the healthcare research analysts here at Goldman Sachs. Pleased to present Genmab and we've got Anthony Pagano, CFO, joining us. Thank you, Anthony. Maybe do you want to just kick off with a bit of background on yourself and then just some high level comments on kind of year-to-date.
/-&
Sure. No, happy to do so. And thanks, Rajan, for having us back at this wonderful conference. And it's great to be here with everybody in the room and those listening virtually, yes. So maybe to off, it's really a super exciting time for us at Genmab, especially if you think about the recent approval of EPKINLY in the United States, and there's a lot more to be excited about with EPKINLY moving forward. Now on top of that, we really are expanding accelerating our entire pipeline and indeed, our entire business. And that's really on top of a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |